glp-1 drug test Personalized Treatments Preparing for the impact of
Description
[PMID: 39681363]
Richard Pollok, Institute for Infection and Immunity, City St Georges University Medical School, London, United Kingdom
During the COVID-19 pandemic, drug manufacturers struggled to keep up with demand
Tirzepatide is the active ingredient in Zepbound, a GLP-1 receptor agonist
Novos CagriSema program is another good example of a combination drug (cagrilintide + semaglutide)
A three-year obesity and prediabetes trial found that LIR 3 mg can improve health benefits in reducing the diabetes risk of patients with obesity and prediabetes (91)
